Últimas noticias sobre Focus Universal (NASDAQ:FCUV) Bolsa

Focus Universal

Focus Universal Inc offers smart devices, IoT products, and patented products and technologies for 5G telecommunications and network security. It is focused on commercializing its universal smart technology and financial reporting software. Its product line includes various digital, analog, and quantum light meters and filtration products, the Ubiquitor universal smart device, SEC Financial Reporting Software, and other smart devices and sensors. The company's reportable segments are Corporate and IoT, which derives maximum revenue, and Perfecular and Lusher. The Corporate and IoT segment includes its LED and IoT installation and management business (under Smart AVX), specializing in LED and display systems, home theaters, lighting control, automation, and integration.

Focus Universal Inc

A <a href="https://www.benzinga.com/news/politics/25/06/45800612/trump-says-musk-has-trump-derangement-syndrome-as-battle-over-bill-heats-up-had-a-great-relationship-dont-know-if-we-will-anymore">highly public feud </a>between Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk and President Donald Trump took the world by storm last week and sent shares of the electric vehicle company lower.
As the feud continues on, here's a look at where Benzinga readers stand.
What Happened: A <a href="https://www.benzinga.com/news/politics/25/06/45821929/trump-vs-musk-president-selling-his-tesla-is-targeting-robotaxis-next">back-and-forth</a> between Musk and Trump across social media platforms saw the two well-known individuals escalate a feud related to differences on the "Big Beautiful Bill."
The feud comes after Musk left his White House position working for the Department of Government Efficiency to spend more time working on his other companies, such as Tesla.
Benzinga recently asked readers who they side with in the battle, which includes Musk criticizing the new debt the country will take on if the bill that Trump supports is passed by Congress.
"In the feud between Donald Trump and Elon Musk, who are you more likely to publicly support?" Benzinga asked.
Here are the results:
<ul class="wp-block-list">
<li>Neither: 44%</li>
<li>Elon Musk: 25%</li>
<li>Donald Trump: 17%</li>
<li>Both: 14%</li>
</ul>
The poll found that a near majority said they would publicly support neither Trump or Musk in the feud between former friends.
Of the two well-known candidates, Musk received the largest support with 25% of the poll, ranking ahead of Trump at 17%.
You may not be a billionaire like Elon Musk, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45827517/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-68">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: Over the weekend, the battle between Musk and Trump minimized some with the Tesla CEO deleting some of his tweets that brought some claims against the current president. Tweets about ending the SpaceX Dragon program were also deleted.
A battle between Trump and Musk over the long run could see many losers, including the country's space program and the launch of robotaxis, with Musk a leader in both sectors and Trump able to slow down progress made by the billionaire.
Tesla stock saw its largest one-day market capitalization drop last week on the heels of the feud. 
Tesla stock trades up 1.61% at $299.72 at publication on Monday versus a 52-week trading range of $167.42 to $488.54. The stock has fallen 15% over the last five days and is down 22% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/space/25/05/45680115/tesla-the-best-elon-musk-company-84-say-no-these-3-rank-higher">Tesla The Best Elon Musk Company? 84% Say No — These 3 Rank Higher</a></li>
</ul>
The study was conducted by Benzinga from June 5, 2025, through June 9, 2025. It included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 259 adults.

Photo: Shutterstock

Entertainment

News

Politics

Exclusives

Trading Ideas

TSLA

Musk Vs. Trump: Poll Says This Is The Person To Support In Feud, While Near Majority Say They Would Publicly Support Neither

Leverage Shares&#8216; launch of RTXG, the first-ever 2X leveraged ETF tracking defense contractor RTX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>), marks a notable shift in the firm's strategy <a href="https://www.benzinga.com/etfs">beyond tech-focused products</a>. 
The ETF launched trading on June 6, a move away from the issuer&#8217;s typical tech-biased product platform.
Leverage Shares 2X Long RTX Daily ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTXG#NASDAQ">RTXG</a>) arrives as investor interest in military-industrial themes grows. RTXG offers amplified daily exposure to a major defense stock at a low management fee. It also appeals to tactical traders seeking short-term momentum plays tied to geopolitical catalysts. 
The ETF&#8217;s launch underscores the broader expansion of single-stock ETFs into traditionally underrepresented sectors like defense and industrials.
RTXG joins a roster of tactical trading instruments targeting retail and institutional investors looking for sharper exposure to market themes.
Also Read: <a href="https://www.benzinga.com/markets/commodities/25/06/45842761/silver-just-shattered-a-14-year-ceiling-could-50-be-next">Silver Just Shattered A 14-Year Ceiling &#8211; Could $50 Be Next?</a>
The fund mirrors RTX&#8217;s daily price fluctuations at 200% leverage, such that a 1% increase (or decrease) in RTX would result in a 2% return (or loss) to RTXG, a high-risk, high-reward trade that is more suitable for short-term trades than for long-term holding.
What distinguishes RTXG in a growingly dense leveraged ETF landscape is its 0.75% management fee, one of the lowest in the group. The action follows Leverage Shares&#8217; doubling its ETF lineup to 16 single-stock funds as part of a wider push to provide additional thematic exposure in defense, energy, and industrials—sectors that often go underrepresented in the leveraged product universe.
The firm attributes its entry into non-tech names as a reaction to changing investor appetite. While RTXG might be attractive to momentum investors speculating on defense outlays or geopolitics tailwinds, advisers warn that leveraged ETFs are best employed with discipline and well-defined exit strategies.
RTX previously did business as Raytheon Technologies.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45841817/us-listed-chinese-stocks-gain-as-us-china-trade-talks-spark-optimism">US Listed Chinese Stocks Gain As US-China Trade Talks Spark Optimism</a></li>
</ul>
Image: Shutterstock

New ETFs

ETFs

RTXG

RTXG ETF Takes Flight With 2X Daily Exposure To Aerospace Giant As Defense Spending Spikes

Citigroup analyst Jason Gursky maintains L3Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) with a Buy and raises the price target from $245 to $280.

Price Target

Analyst Ratings

Citigroup Maintains Buy on L3Harris Technologies, Raises Price Target to $280

UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) is reportedly weighing multiple offers for its Latin American business as it scrambles to recover from a string of corporate stumbles, including a leadership shakeup and a <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">reported federal investigation</a>.
The potential sale, involving its Banmedica unit, comes as the company seeks to restore shareholder confidence and streamline operations under new leadership.
In May, UnitedHealth's CEO, Andrew Witty,&nbsp;resigned for personal reasons.&nbsp;Stephen Hemsley, who previously held the CEO title from 2006 to 2017,&nbsp;<a target="_blank" href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance" rel="noreferrer noopener">succeeded him</a>. The company also suspended its 2025 outlook.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45624067/unitedhealth-hits-2008-era-oversold-levels-as-citadel-advisors-sells-fisher-buys" rel="noreferrer noopener">UnitedHealth Hits 2008-Era Oversold Levels As Citadel Advisors Sells, Fisher Buys</a>
In an SEC filing on Wednesday, UnitedHealth&nbsp;<a target="_blank" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/731766/000073176625000154/unh-20250602.htm&amp;tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">said</a> it canceled the performance-based restricted stock units granted to Witty,
Year to date, UnitedHealth's stock has plunged almost 40%, with the majority coming after the disappointing fourth-<a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43025159/unitedhealth-q4-earnings-revenue-falls-short-medical-ratio-rises-to-85-5-stock-falls" rel="noreferrer noopener">quarter 2024 earnings</a>.
After reporting weaker-than-expected earnings and facing allegations of Medicare fraud—currently not formally acknowledged by the Department of Justice—UnitedHealth is <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45775858/unitedhealth-board-reelects-directors-hikes-dividend-as-ceo-pledges-review-of-medicare-practices" rel="noreferrer noopener">shifting its focus</a>.
Reuters notes that the insurance giant has been working to exit Latin America since 2022, but recent developments have heightened the urgency of its plans.
UnitedHealth's aggressive growth strategy under Witty exposed the healthcare giant to mounting regulatory scrutiny, soaring costs, and a&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">shifting Medicare landscape</a>.
Hemsley is stepping forward to acknowledge the fallout and chart a new course, promising a comprehensive review of some of the company's most controversial practices.
Citing individuals familiar with the matter, Reuters reported UnitedHealth had received four non-binding bids for Banmedica, which operates in Colombia and Chile. The bids reportedly value the business at approximately $1 billion.
Interested parties include Acon Investments, Patria Investments, Christus Health, and Auna, with the latter exploring a financial partnership to support its offer.
The company aims to set a July deadline for binding proposals for Banmedica, which generates more than $200 million in annual EBITDA.
Banmedica <a target="_blank" href="https://www.financierworldwide.com/fw-news/2018/1/2/unitedhealth-to-acquire-banmdica" rel="noreferrer noopener">was</a> acquired in 2018 as part of UnitedHealth's plan to expand across South America. Then, CEO David Wichmann touted the deal as a foundation for growth for decades. However, financial challenges led the company to reverse.
UnitedHealth previously exited Brazil in late 2023 and Peru earlier this year.
UnitedHealth recorded an $8.3 billion loss tied to its South American operations—$7.1 billion from Brazil and $1.2 billion from Banmedica.
Though Banmedica remains profitable, with over 2.1 million insurance members and about 4 million patient visits annually across its 13 hospitals and 143 medical centers, UnitedHealth now views it as too small to align with its long-term strategic goals.
Price Action: UNH stock is down 0.51% at $301.67 at the last check on Monday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45796533/humana-backs-reforms-to-limit-medicare-advantage-billing-practices" target="_blank" rel="noreferrer noopener">Humana Backs Reforms To Limit Medicare Advantage Billing Practices</a></li>
</ul>
Photo by Ken Wolter via Shutterstock

Large Cap

Health Care

Rumors

Asset Sales

Media

General

UnitedHealth Eyes Retreat From Latin America After $8.3 Billion Loss

Citigroup analyst Jason Gursky maintains Karman Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRMN#NYSE">KRMN</a>) with a Buy and raises the price target from $46.5 to $58.

KRMN

Citigroup Maintains Buy on Karman Holdings, Raises Price Target to $58

Citius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) shares are trading higher Monday after the company announced it entered into a distribution services agreement <a href="https://www.benzinga.com/pressreleases/25/06/n45834791/citius-oncology-enters-into-distribution-services-agreement-with-cardinal-health">with Cardinal Health</a>.
The Details: Cities entered into a distribution services agreement with Cardinal Health to help provide access to LYMPHIR (denileukin diftitox-cxdl), an FDA-approved immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma, in support of its anticipated U.S. commercial launch.
Under the agreement, Cardinal will serve as an authorized distributor of record for Citius Oncology providing specialty pharmaceutical distribution services. &#8220;This agreement marks a key step forward in our launch readiness efforts,&#8221; said Leonard Mazur, chairman and CEO of Citius Oncology and Citius Pharmaceuticals.
&#8220;Cardinal Health&#8217;s proven distribution capabilities will help ensure LYMPHIR reaches healthcare providers and patients efficiently and reliably, as we work to build a robust commercial distribution network.&#8221;
CTXR Price Action: At the time of publication Monday, Citius Pharmaceuticals shares were up 100.9% at $1.73, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwiFq8zk8eSNAxXOm4kEHc9sFlAQFnoECAoQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45843490/jm-smucker-likely-to-report-lower-q4-earnings-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">JM Smucker Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>
Image via Shutterstock.

Movers

CTXR

Citius Pharmaceuticals Stock Is Soaring Monday: What's Going On?

Citigroup analyst Jason Gursky maintains Curtiss-Wright (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CW#NYSE">CW</a>) with a Buy and raises the price target from $444 to $520.

Citigroup Maintains Buy on Curtiss-Wright, Raises Price Target to $520

WIIM

Advanced Micro Devices shares are trading higher after Citigroup raised its price target on the stock from $100 to $120.

MSTR

MicroStrategy shares are trading higher after the company announced it acquired another 1,045 BTC For $110.2 million between June 2-June 8.

Arm Holdings shares are trading higher after Benchmark reiterated its Hold rating on the stock.

Dogecoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) relatively flat performance over the past week has market commentators speculating about two important liquidation levels <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">for the meme coin</a>.
What Happened: Crypto trader Trader Tardigrade noted that Dogecoin's liquidation heatmap reveals two major liquidity targets above the current price:
<ul class="wp-block-list">
<li>$0.189 with $2.46 billion in liquidity</li>
<li>$0.1995 with $2.14 billion in liquidity</li>
</ul>
These are likely areas market makers will aim for, suggesting upward price potential.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> Liquidation Heatmap shows two significant liquidation levels above the current price. The highest level is at $0.189 with $2.46B in liquidity, and the second is at $0.1995 with $2.14B in liquidity. Market makers are aware of these levels, so you don&#39;t have to worry… <a href="https://t.co/U79beCdfpM">pic.twitter.com/U79beCdfpM</a>
&mdash; Trader Tardigrade (@TATrader_Alan) <a href="https://twitter.com/TATrader_Alan/status/1932056863702741095?ref_src=twsrc%5Etfw">June 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trader Hardy <a href="https://x.com/Degen_Hardy/status/1932025566821335307">observed</a> Dogecoin has returned to a strong support zone, potentially setting up a new long opportunity. The chart will be closely monitored over the next few days for confirmation.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45833498/bitcoin-ethereum-xrp-dogecoin-start-the-week-green-ahead-of-us-china-trade-talks">Bitcoin, Ethereum, XRP, Dogecoin Start The Week Green Ahead Of US-China Trade Talks</a>
Why It Matters: Pseudonymous developer PennybagsCX <a href="https://x.com/PennybagsCX/status/1932114088777203906">stated</a> that Dogechain, launched in 2022, is quietly transforming Dogecoin from a meme-based currency into a full-fledged utility ecosystem.
As an EVM-compatible blockchain, Dogechain enables smart contracts and allows DOGE to be bridged and used for transactions across a growing suite of applications. 
This includes gaming dApps, NFT marketplaces, and DeFi protocols like lending, borrowing, and yield farming, all powered by DOGE.
By expanding Dogecoin's use cases beyond simple payments, Dogechain is unlocking new opportunities for holders and helping build a vibrant, utility-driven future for the Doge community.
Coinglass data shows Dogecoin's open interest is up by 1.3% to $1.99 billion, while derivatives trading volume expanded by 25.4% in a single day. 
Options volume and options open interest expanded by 1,829% and 502.9%, respectively.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45819356/dogecoin-down-10-on-the-week-is-the-musk-trump-spat-bearish-for-doge">Dogecoin Down 10% On The Week: Is The Musk-Trump Spat Bearish For DOGE?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

What Is Dogecoin's Next Move? Watch These 2 Liquidation Levels, Trader Warns

AAPL

GPRO

Watching GoPro; Shares Spike Higher, Apple Announces 'VisionOS 26 supports native playback of 180-degree, 360-degree, and wide field-of-view content from Insta360, GoPro, and Canon'

Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) on Monday shared topline results from the first two of three Phase 3 clinical trials evaluating the safety and efficacy of enlicitide decanoate, an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor for hyperlipidemia on lipid-lowering therapies, including <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">at least a statin</a>.
Hyperlipidemia&nbsp;refers to having high levels of lipids (fats) in the blood, including cholesterol and triglycerides.&nbsp;It&#8217;s a condition that can increase the risk of heart disease and other health problems.&nbsp;
The CORALreef HeFH and CORALreef AddOn trials met their primary and all key secondary endpoints, demonstrating statistically significant and clinically meaningful greater reductions in low-density lipoprotein <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45832810/merck-announces-positive-topline-results-from-the-first-two-phase-3-coralreef-trials-evaluating-en" rel="noreferrer noopener">cholesterol (LDL-C) for</a>:
<ul class="wp-block-list">
<li>Enlicitide compared to placebo (CORALreef HeFH) and other oral non-statin therapies (CORALreef AddOn).</li>
<li>There were no clinically meaningful differences in incidences of adverse events (AE) and serious adverse events (SAE) in either trial.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/news/health-care/25/06/45743008/mercks-dealmaking-intensifies-with-moonlake-bid-as-keytruda-patent-cliff-nears-report" target="_blank" rel="noreferrer noopener">Merck&#8217;s Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report</a>
Results from the three Phase 3 trials in the&nbsp;CORALreef clinical development program&nbsp;will be presented at a future scientific congress.
Key takeaways from CORALreef HeFH and CORALreef AddOn studies:
<ul class="wp-block-list">
<li>CORALreef HeFH: Statistically significant and clinically meaningful reductions in LDL-C for enlicitide versus placebo in adults with heterozygous familial hypercholesterolemia (HeFH) who have a history of or are at risk for atherosclerotic cardiovascular disease (ASCVD) and are treated with a statin.</li>
<li>CORALreef AddOn: Statistically significant and clinically meaningful reductions in LDL-C for enlicitide versus ezetimibe, versus bempedoic acid and versus ezetimibe and bempedoic acid in adults with hyperlipidemia who have a history of or are at risk for ASCVD and are treated with a statin.</li>
</ul>
The efficacy and safety of enlicitide are being evaluated through the comprehensive&nbsp;CORALreef Phase 3 clinical development program, which <a target="_blank" href="https://www.merck.com/wp-content/uploads/sites/124/2025/06/CORALreef_Clinical_Trial_Explainer.pdf" rel="noreferrer noopener">aims</a> to enroll approximately 17,000 patients across several trials, including two large ongoing trials, CORALreef Lipids and CORALreef Outcomes.
Price Action: MRK stock is trading higher by 0.19% to $79.12 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45841878/analyst-says-newamsterdam-stock-has-over-100-upside-citing-90-success-probability-for-obicetrapib" target="_blank" rel="noreferrer noopener">Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib</a></li>
</ul>
Photo by tada images via Shutterstock

Biotech

Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials

OKLO

Oklo shares are trading higher after Seaport Global upgraded the stock from Neutral to Buy and announced a $71 price target.

WBD stock has given up its prior gain. Warner Bros Discovery shares were trading higher. The company announced plans to separate the company into two publicly traded companies.

Citigroup analyst Christopher Danely maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Buy and raises the price target from $55 to $68.

MCHP

Citigroup Maintains Buy on Microchip Technology, Raises Price Target to $68

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has quietly joined the ranks of <a href="https://www.benzinga.com/topic/s-p-500-index">the S&amp;P 500</a>'s biggest EPS disappointments in the first quarter.
According to <a href="https://advantage.factset.com/hubfs/Website/Resources%20Section/Research%20Desk/Earnings%20Insight/EarningsInsight_060625A.pdf">FactSet</a>, Tesla landed in the bottom 10 for Actual EPS Surprise %, with its first quarter earnings missing expectations by a stark 25.3% ― a notable spot of underperformance for the EV leader.
<h2 class="wp-block-heading">Tesla's EPS Shock: A Quarter To Forget</h2>
That 25% miss puts Tesla alongside companies like Norwegian Cruise Line Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) and First Solar Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) ― far from its usual club of beats.
The data paints a different portrait than the company's headline-grabbing innovations: Tesla is being lumped in with chicken-footed performers, not the industry disruptors.
Read Also: <a href="https://www.benzinga.com/markets/asia/25/06/45834491/tesla-china-sales-surge-in-may-as-new-model-y-juniper-exported-for-the-first-time-amid-us-china-trade-war">Tesla China Sales Surge In May As New Model Y Juniper Exported For The First Time Amid US-China Trade War</a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0609"><img loading="lazy" decoding="async" width="628" height="487" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09120643/Screenshot-2025-06-09-at-7.41.54-PM.png" alt="" class="wp-image-943497" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09120643/Screenshot-2025-06-09-at-7.41.54-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09120643/Screenshot-2025-06-09-at-7.41.54-PM-300x233.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0609">Chart created using Benzinga Pro</a>
<h2 class="wp-block-heading">Can TSLA Chart Hold The Line At ~$290?</h2>
Despite the miss, TSLA remains a tale of two markets. Over the past 12 months, it's up nearly 70%, but it has stumbled –22% year-to-date, trading near $293 ― well below both its eight-day and 20-day simple moving averages (SMAs), marking a crisp bearish signal . A deeper dip below this range could signal more technical pain.
Still, Tesla stock manages mixed signals. Its 50-day SMA at $292.32 sits just under current levels, hinting at a possible floor. Meanwhile, the MACD (moving average convergence/divergence) indicator remains positive and the RSI (relative strength index) floats around neutral, signaling technical balance but little conviction .
Why the miss? Production snags. Price cuts that carved into margins. Questions around demand ― especially as EV competition heats up and macro uncertainty lingers.
That said, Tesla's long-term narrative remains intact: its energy business is scaling, global expansion continues, and recurring software and FSD revenue could restore margin optimism.
<h2 class="wp-block-heading">What&#8217;s Next For TSLA Investors?</h2>
TSLA investors may want to keep an eye on:
<ul class="wp-block-list">
<li>Tesla&#8217;s second quarter guidance and any recalibration in price strategy.</li>
<li>The stock&#8217;s technical support and whether it holds around the $290–295 zone or gives way to deeper downside.</li>
<li>A shift in narrative &#8211; if Tesla leans back into margin talk and software recurring revenues, the stock could rebound despite short-term jitters.</li>
</ul>
The investors' dilemma is clear: Tesla may be among the S&amp;P's most disappointing EPS misses in the first quarter, but is that a signal of long-term trouble &#8211; or just a short-lived blip?
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45834012/tom-lee-dismisses-worries-over-tumbling-tsla-stock-amid-elon-musk-trump-feud-tesla-still-holds-all-of-its-advantages-so-we-arent-too-concerned">Tom Lee Dismisses Worries Over Tumbling TSLA Stock Amid Elon Musk-Trump Feud: &#8216;Tesla Still Holds All Of Its Advantages, So We Aren&#8217;t Too Concerned&#8217;</a></li>
</ul>
Photo: Shutterstock

Equities

Technicals

Tech

FSLR

NCLH

Tesla Among S&P's Big Losers: Q1 EPS Miss Puts TSLA In Bottom 10

Morgan Stanley analyst Annelies Vermeulen maintains Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) with a Overweight and raises the price target from $195 to $220.

FERG

Morgan Stanley Maintains Overweight on Ferguson Enterprises, Raises Price Target to $220

Metsera, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) on Monday released topline data from the Phase 1 clinical trial of MET-233i, an ultra-long-acting amylin analog engineered for class-leading durability, potency and combinability with Metsera&#8217;s fully-biased monthly GLP-1 <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">receptor agonist candidate</a>, MET-097i.
In the study, MET-233i demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36, a 19-day observed half-life supporting once-monthly dosing, and a favorable tolerability profile <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45832929/metsera-announces-positive-phase-1-data-of-first-in-class-once-monthly-amylin-candidate-met-233i" rel="noreferrer noopener">with no safety signals</a>.
MET-233i was evaluated at single doses from 0.15 mg to 2.4 mg and multiple doses from 0.15 mg to 1.2 mg given once weekly over five weeks without titration.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/market-summary/25/03/44102235/why-did-metsera-stock-surge-15-on-the-worst-trading-day-of-2025-heres-what-has-happened-since-its-listing" rel="noreferrer noopener">Why Did MTSR Stock Surge 15% On The Worst Trading Day Of 2025? Here&#8217;s What Has Happened Since Its Listing</a>
Topline results from the Phase 1 trial include:
<ul class="wp-block-list">
<li>Dose-linear pharmacokinetics with an observed half-life of 19 days&nbsp;from dose to 50% of Cmax, supporting the potential for once-monthly dosing with simplified titration.</li>
<li>Body weight loss was dose-dependent, ranging from a placebo-subtracted mean of 8.4% at Day 36 after five weekly doses of 1.2 mg, with individual responses as high as 10.2%. 
<ul class="wp-block-list">
<li>In the trial&#8217;s single ascending dose (SAD) portion, substantial weight loss was maintained more than four weeks after dosing, supported by the ultra-long pharmacokinetics observed for MET-233i.</li>
</ul>
</li>
<li>Gastrointestinal adverse events in the trial&#8217;s multiple ascending dose (MAD) portion were all mild, dose-dependent, and primarily confined to the first week of dosing, implying rapid tolerance onset despite a three-fold exposure accumulation over five weeks. Anticipated starting doses of 0.15 mg and 0.3 mg demonstrated tolerability results comparable to placebo in both the trial&#8217;s SAD and the MAD portions.</li>
<li>To date, no severe or serious adverse events have been observed in the SAD or MAD portion of the trial.</li>
</ul>
Next Steps: Based on these positive topline data, Metsera is rapidly advancing MET-233i as a monotherapy and in combination with MET-097i:
<ul class="wp-block-list">
<li>An ongoing monotherapy trial evaluates 12 weekly doses of MET-233i with dose titration, followed by an exposure-matched monthly dose at week 13. Topline data from this trial are expected in late 2025.</li>
<li>Metsera has extended an ongoing co-administration trial of MET-233i and MET-097i to 12 weeks. Topline data are expected by year-end 2025 or early 2026.</li>
</ul>
The company also expects to report topline clinical data from its ultra-long-acting GIP receptor agonist, MET-034i, in combination with MET-097i, in late 2025.
The company anticipates that MET-034i will be the third peptide engineered with Metsera&#8217;s HALO platform to enter clinical testing.
MTSR Price Action: Metsera stock is up 13.24% at $31.13 at publication on Monday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45834370/eli-lillys-obesity-drug-success-spurs-japanese-biotechs-anti-muscle-wasting-combo-therapy" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s Obesity Drug Success Spurs Japanese Biotech&#8217;s Anti-Muscle-Wasting Combo Therapy</a></li>
</ul>
Photo: Shutterstock

MTSR

Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data

Citigroup analyst Christopher Danely maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Neutral and raises the price target from $100 to $120.

Citigroup Maintains Neutral on Advanced Micro Devices, Raises Price Target to $120

Events

Press Releases

Focus Universal to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Bitech Technologies (OTCQB: BTTC) Revolutionizes Grid Stability with Advanced Smart Energy Storage Solutions SIFY LGMK FCUV CBDW

Focus Universal Inc. Announces Pricing of $1.2 Million Registered Direct Offering

Univest Securities, LLC Announces Closing of $1.2 Million Registered Direct Offering for its Client Focus Universal Inc. (NASDAQ: FCUV)

Focus Universal Inc. Announces Listing Transfer to Nasdaq Capital Market

Focus Universal Inc. Announces Appointment of Professor Shivaram Rajgopal to Advisory Board

Focus Universal Inc. to Showcase Universal Smart Device and Universal Smart IoT Platform at CES 2025

Focus Universal Announces Reverse Stock Split

Focus Universal Inc. Regains Compliance with Nasdaq Listing Requirement

Focus Universal Inc. to Participate in Centri Capital Conference

BTTC

CBDW

FCUV

LGMK

SIFY

Astrotech

Cemtrex

Coda Octopus Group

Digital Ally

Electro-Sensors

Identiv

AEye

Interlink Electronics, Inc. - Common Stock

Interlink Electronics

LightPath Technologies, Inc. - Class A Common Stock

LightPath Technologies

MultiSensor AI Holdings, Inc. - Common Stock

MultiSensor AI Holdings

Maris Tech

NOVONIX Limited - American Depository Shares

NOVONIX

Research Frontiers Incorporated - Common Stock

Research Frontiers

SmartRent

SMX (Security Matters) Public Limited Company - Class A Ordinary Shares

SMX (Security Matters)

Sobr Safe

Sono-Tek

ScanTech AI Systems

SaverOne 2014 Ltd. - American Depositary Shares

Saverone 2014

TROOPS

Unusual Machines

Universal Security Instruments, Inc. Common Stock

Universal Security

VerifyMe

Wrap Technologies

Zepp Health Corporation American depositary shares, each representing sixteen Class A ordinary shares

Zepp Health

Comments

Focus Universal

Noticias

Últimas noticias sobre Focus Universal (NASDAQ:FCUV) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL